We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

This study has been terminated.
(Lower than anticipated recruitment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01007851
First Posted: November 4, 2009
Last Update Posted: November 4, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
V.K.V. American Hospital, Istanbul
  Purpose
GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Condition Intervention Phase
Infertility Drug: triptorelin acetate Drug: NaCl %0.9 Phase 3

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by V.K.V. American Hospital, Istanbul:

Primary Outcome Measures:
  • Ongoing pregnancy beyond 20th gestational week

Secondary Outcome Measures:
  • clinical pregnancy rate
  • Embryo implantation rate

Study Start Date: September 2006
Study Completion Date: December 2007
Arms Assigned Interventions
Experimental: GnRH agonist Drug: triptorelin acetate
single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
Placebo Comparator: Saline Drug: NaCl %0.9
0.1 ml sterile saline sc injection 3 days after embryo transfer

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
  • Embryo transfer performed on day 3

Exclusion Criteria:

  • Participation in another trial that was being conducted in our unit at the same time.
  • Preimplantation genetic screening cycles.
  • Day 5 embryo transfers.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01007851


Locations
Turkey
American Hospital
Istanbul, Turkey, 34365
Sponsors and Collaborators
V.K.V. American Hospital, Istanbul
  More Information

ClinicalTrials.gov Identifier: NCT01007851     History of Changes
Other Study ID Numbers: AH-48/07
First Submitted: November 3, 2009
First Posted: November 4, 2009
Last Update Posted: November 4, 2009
Last Verified: November 2009

Keywords provided by V.K.V. American Hospital, Istanbul:
GnRH agonist
GnRH antagonist
IVF
ICSI
assisted reproduction
luteal phase

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents